Gallbladder Neoplasms Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Gallbladder Neoplasms. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Gallbladder Neoplasms receives a directional score of 58/100, combining unmet need (72/100), competitive intensity (96/100) and market attractiveness (80/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

Tumors or cancer of the gallbladder.

The reproducible record is Patsnap disease ID f04e110974bf45b58dd4d2eabcd2c6c1 and MeSH identifier D005706. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: Gallbladder and biliary tract cancer burdens in China from 1990 to 2021 and projection to 2044: findings from the 2021 Global Burden of Disease study

Introduction Gallbladder and biliary tract cancers (GBTCs) are a heterogeneous and aggressive group of adenocarcinomas characterized by high morbidity and mortality rates (1, 2). Only a subset of patients with early-stage GBTCs can achieve a cure through surgical resection or liver transplantation (under stringent selection criteria); however, the majority of GBTC patients present with incurable locally advanced or metastatic disease due to delayed detection and thus have an exceedingly unfavorable prognosis, with only 2–5% for 5-year overall survival (3–5). In 2020, there were 115,949 new cases and 84,695 new deaths from GBTCs worldwide, ranking 25th and 21st among the 36 cancers, respectively (6). Despite accounting for only approximately 3% of all digestive system tumors, GBTC still imposes a significant societal and economic burden due to its unfavorable prognosis (7).h The burden of disease evaluation currently serves as a comprehensive assessment system for quantifying the health impact of diseases and risk factors across diverse geographical regions, generations, age groups, and sexes. The distribution of GBTCs varies significantly globally, and the mortality rates of GBTCs have exhibited a downward trend in most countries worldwide. Certain high-income nations have experienced an upward trajectory in recent years (8–10). Moreover, previous studies have shown that the incidence and mortality rates of GBTCs are typically higher in Asia and South America than in high-income countries, such as China and Thailand, where the incidence is 40 times higher (1, 11, 12). China

Review source

Epidemiology evidence 2: Cancer Statistics for the US Hispanic/Latino Population, 2021

Gallbladder cancer incidence and mortality trends are similar because of the high fatality rate. Over the past decade, incidence rates declined by approximately 1.5% per year in Hispanic individuals compared to 1% per year in NHWs (Table 4). Similarly, gallbladder cancer death rates declined by about 2.5% per year and 2% per year in Hispanic and NHW people, respectively. The disease typically does not exhibit symptoms until it is advanced, resulting in a late stage at diagnosis and a poor prognosis. The 5-­year survival rate, which is similar by sex, is 18% among Hispanic patients and 20% among NHW patients. Approximately 1 in 7 Hispanic patients are diagnosed at a localized stage, for which 5-­year relative survival is 62%. However, most patients are typically diagnosed with regional-­ or distant-­stage disease, for which 5-­year relative survival declines to 26% and 2%, respectively. Liver and intrahepatic bile duct In 2021, an estimated 7100 Hispanic men and women will be diagnosed with liver cancer, and 4100 will die from the disease. Incidence rates in Hispanic men and women are double those in NHWs (Table 2), similar to non-­White ra- cial and ethnic groups in the United States.32 Notably, the risk of liver cancer in US-­born Hispanic men is double that in foreign-­born men.76 For example, liver cancer death rates in California among US-­born Mexican men were 21.6 per 100,000 during 2008 through 2012 versus 11.8 per 100,000 among foreign-­born Mexican men.9 The cause for this pat- tern is unclear but may reflect greater acculturation and a higher prevalence of liver c

Review source

Epidemiology evidence 3: Cancer Statistics for Hispanics/Latinos, 2012

There will be an estimated 600 cases of gallbladder and other biliary cancers diagnosed among Hispanic men and women in 2012. Information on gallbladder cancer in the scientific literature is scant relative to other cancers due to its rarity, particularly in economically developed countries. In the United States, gallbladder cancer accounts for only 0.2% of all cancer cases among NHWs and 0.5% of cases among Hispanics. Incidence and mortality rates among Hispanics are about twice those of NHWs (Table 2). It is one of the few cancers that occurs more often in women than in men; His- panic women have the highest burden of any race/ethnicity.15 Gallbladder cancer typically presents with vague symptoms, resulting in a late stage at diagnosis and poor prognosis; 5-year survival rates are 21.7% among Hispanics and 17.8% among NHWs.13 Incidence rates are decreasing by 1.1% per year among Hispanic and NHW women, by 3.4% per year among Hispanic men, and are stable in NHW men (Table 3). Death rates are decreasing in all 4 groups, although the trend in Hispanics is not statistically significant. Although generally rare, the incidence of gallbladder cancer varies tremendously worldwide, particularly among women, and is very high in some regions.144,145 Rates are among the highest in the South American countries of Ecuador, Colombia, Uruguay, and Chile.144,146 Notably, gallbladder cancer is the most common cause of cancer death among Chilean women, exceeding breast and cervical cancers.146 A study of the wide geographic variation of gallbladder cancer within Chile found that mortality rat

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Gallbladder Neoplasms, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Gallbladder Neoplasms thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor is PTH1R, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 505 registered studies.

• NCT07780838 — Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for the Treatment of Unresectable, Locally Advanced or Metastatic Biliary Tract Cancers With FGFR2 Alterations; Not yet recruiting; Phase 2; sponsor Ohio State University Comprehensive Cancer Center, Incyte Corp.; enrollment 29.
• NCT07767994 — AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer (ICORE-GBC); Not yet recruiting; Phase 2; sponsor First Affiliated Hospital of Xi'an Jiaotong University; enrollment 22.
• NCT07765433 — Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer; Not yet recruiting; Phase 2/3; sponsor ECOG-ACRIN Medical Research Foundation, Inc., National Cancer Institute; enrollment 336.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate PTH1R relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Gallbladder Neoplasms merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Gallbladder Neoplasms is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.